Occupational Activity
Endpoints 11: Biopharma’s most promising startups revealed live in Boston this September
Endpoints 11; biotech startups; biopharma; Boston event; State Room; awards gala; early bird rate; industry insiders; 2025 most promising biotechs; real-time reveal
Agentic AI is Here: Real-World Applications in Life Sciences & Healthcare (2025 Update)
Agentic AI; life sciences; healthcare; R&D; pharma; personalized medicine; pharmacovigilance; commercialization; automation; data analysis
Elevidys Sales Surge in Sarepta Q2 2025 Despite Safety Concerns
Sarepta Therapeutics; Elevidys; Q2 2025; gene therapy; sales performance; FDA; safety issues; shipment pause
Novo Nordisk’s Leadership Shakeup and Wider Implications; Ex-FDA Official Takes Regulatory Role at GSK
Novo Nordisk; leadership shakeup; new CEO; Maziar Mike Doustdar; share price drop; obesity drug market; competition; GSK; regulatory affairs; Former FDA
Trump Administration Unveils Health Data Sharing Scheme Backed by Apple, Amazon, and Others
Trump administration; health data sharing; CMS Interoperability Framework; Apple; Amazon; digital health records; patient data; privacy; tech partnerships
Ignoring China’s Biotech Industry Is No Longer an Option: Recent Developments and Implications
China biotech industry; global drug development; clinical trials; innovation ecosystem; pharmaceutical R&D; biotech patents; US-China competition
Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance
Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition
Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges
Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations
Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul
Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development
CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling
Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion